Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of VERA is 76 and suggests 61% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell